Home/Pipeline/CRD-1968099

CRD-1968099

Oncology/Immunology

PreclinicalActive

Key Facts

Indication
Oncology/Immunology
Phase
Preclinical
Status
Active
Company

About Chordia Therapeutics

Japanese biotech developing novel small molecule kinase inhibitors for oncology and immunology, with multiple clinical-stage assets.

View full company profile

Therapeutic Areas

Other Oncology/Immunology Drugs

DrugCompanyPhase
BTKRecludix PharmaPre-clinical